BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:mRESVIA readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of mRESVIA\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05743881-10900@assetmemo.bio
DTSTAMP:20261121T005626Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:mRESVIA: Phase 1 readout est. (NCT05743881)
DESCRIPTION:mRESVIA\, phase 1.\nStudy: A Safety\, Tolerability\, and Immuno
 genicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to
  <24 Months\nEstimated primary completion: 31 August 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/mresvia#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05743881
URL:https://assetmemo.bio/drug/mresvia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
